EQL Pharma AB (publ) reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was SEK 60.33 million compared to SEK 203.03 million a year ago. Net income was SEK 4.12 million compared to SEK 6.51 million a year ago. Basic earnings per share from continuing operations was SEK 0.14 compared to SEK 0.22 a year ago.
For the full year, sales was SEK 259.91 million compared to SEK 409.75 million a year ago. Net income was SEK 30.92 million compared to SEK 31.55 million a year ago. Basic earnings per share from continuing operations was SEK 1.06 compared to SEK 1.09 a year ago.